{"Title": "Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?", "Year": 2017, "Source": "Neurology", "Volume": "89", "Issue": 11, "Art.No": null, "PageStart": 1098, "PageEnd": 1100, "CitedBy": 8, "DOI": "10.1212/WNL.0000000000004381", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85033578773&origin=inward", "Abstract": null, "AuthorKeywords": null, "IndexKeywords": ["Alemtuzumab", "Antibodies, Monoclonal, Humanized", "Humans", "Multiple Sclerosis"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 2, "EID": "2-s2.0-85033578773", "SubjectAreas": [["Neurology (clinical)", "MEDI", "2728"]], "AuthorData": {"55018880100": {"Name": "Wiendl H.", "AuthorID": "55018880100", "AffiliationID": "60000401", "AffiliationName": "Department of Neurology, University of Muenster"}, "7006541853": {"Name": "Bourdette D.", "AuthorID": "7006541853", "AffiliationID": "60032702", "AffiliationName": "Department of Neurology, Oregon Health and Science University"}, "7003671038": {"Name": "Ciccarelli O.", "AuthorID": "7003671038", "AffiliationID": "60019953, 60022148", "AffiliationName": "Department of Neuroinflammation, UCL Institute of Neurology, University College London"}}}